Home
Search:
1146 feeds
357 categories
6489 articles (<24 hours)
19 registered users

Use the Mobile version
Mobile

Follow our Twitter feed

View our Linkpartners
Links

Username:
Password:

Register | Retrieve

Science


Valid HTML 4.01 Transitional

RSS FeedsTyvyt (Sintilimab Injection), an Innovative PD-1 Inhibitor Jointly Developed by Innovent and Lilly, is Included in the New Catalogue of National Reimbursement Drug List (NRDL)
(WorldNews Health)

 
 

28 november 2019 07:19:24

 
Tyvyt (Sintilimab Injection), an Innovative PD-1 Inhibitor Jointly Developed by Innovent and Lilly, is Included in the New Catalogue of National Reimbursement Drug List (NRDL)
(WorldNews Health)
 




SUZHOU, China, Nov. 27, 2019 /PRNewswire/ -- Innovent Biologics, Inc. (`Innovent`) (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic and other major diseases, today jointly announced with Eli Lilly and Company (`Lilly`) that the innovative PD-1 inhibitor TyvytŪ (sintilimab injection), co-developed by both companies, is the only PD-1 inhibitor that has been included in the new Catalogue of National Reimbursement Drug List (`NRDL`) according to the latest announcement from the National Healthcare Security Administration (`NHSA`). (Details of medical insurance reimbursement and...
 
577 viewsCategory: Science > Medicine
 
KFL NAV as at 27/11/19 - $1.6175
(WorldNews Health)
Worldwide Bromodomain Containing Protein 4 Market Survey Report 2020 Along With Statistics Forecasts Till 2029
(WorldNews Health)
 
 
blog comments powered by Disqus


Copyright © 2008 - 2019 Indigonet Services B.V.. Contact: Tim Hulsen. Read here our privacy notice.
Other websites of Indigonet Services B.V.: Nieuws Vacatures Science Tweets Travel Photos Nachrichten Indigonet Finances Leer Mandarijn